Using flow cytometric techniques capable of detecting 0.01% leukemic cells, we prospectively studied minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) after first relapse. At the end of remission reinduction, 41 patients had a bone marrow sample adequate for MRD studies; 35 of these were in morphologic remission. Of the 35 patients, 19 (54%) had MRD X0.01%, a finding that was associated with subsequent leukemia relapse. The 2-year cumulative incidence of second leukemia relapse was 70.2712.3% for the 19 MRDpositive patients and 27.9712.4% for the 16 MRD-negative patients (P ¼ 0.008). Among patients with a first relapse off therapy, 2-year second relapse rates were 49.1717.8% in the 12 MRD-positive and 0% in the 11 MRD-negative patients (P ¼ 0.014); among those who received only chemotherapy after first relapse, the 2-year second relapse rates were 81.5714.4% (n ¼ 12) and 25.0713.1% (n ¼ 13), respectively (P ¼ 0.004). Time of first relapse and MRD were the only two significant predictors of outcome in a multivariate analysis. We conclude that MRD assays should be used to guide the selection of postremission therapy in patients with ALL in first relapse.
Introduction
In approximately 20% of children with acute lymphoblastic leukemia (ALL), disease recurs despite intensive multiagent chemotherapy. 1 Relapse is the most common cause of treatment failure in childhood ALL; relapsed ALL is as common as most pediatric solid tumors and more common than acute myeloid leukemia in childhood. 2 With current therapy, second remissions are achieved in the majority of patients, but overall cure rates seldom exceed 30%. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Clinical features that predict poorer outcome in patients with relapsed ALL include shorter duration of first remission 4, 12, 15, 16 and relapse in the bone marrow. 12, 17, 18 Adverse biologic features include T-cell immunophenotype 5, 18 and Philadelphia chromosome. 19 Assays of minimal, that is, submicroscopic, minimal residual disease (MRD) provide strong prognostic information in children with newly diagnosed ALL, [20] [21] [22] [23] [24] [25] [26] and such assays are increasingly used to select intensity of postremission treatment. 27, 28 Retrospective studies with stored samples have suggested that MRD could also be prognostically important in patients who achieve a second remission, 29, 30 but incorporation of MRD assays into treatment protocols for relapsed ALL requires further clarification of its clinical significance and of its relation with other features of the disease. Here, we report the results of a prospective study of MRD assayed by four-color flow cytometry at the end of remission reinduction in patients with ALL in first relapse.
Materials and methods

Patients
We prospectively studied bone marrow samples obtained from patients with ALL in first relapse enrolled in the St Jude Children's Research Hospital studies for first relapse ALL between March 1993 and March 2003. The only criteria for inclusion in the study was the availability of a sample at diagnosis and/or relapse (to identify suitable immunophenotypes for flow cytometric studies of MRD) and of an adequate bone marrow at the end of remission induction for MRD studies. We studied the leukemia immunophenotypes in 57 patients (40 with B-lineage and 17 with T-lineage ALL) aged 8 months to 21 years (median, 10 years). Cells in 52 of the 57 patients (91%) expressed phenotypes suitable for flow cytometric studies of MRD. 31, 32 Of these, 41 had a sample obtained at the end of remission reinduction (day 36) with sufficient cells for flow cytometric studies of MRD. Rate of remission failure and second ALL relapse for these 41 patients were not significantly different than those of the 16 patients who could not be studied because of the lack of suitable phenotype or lack of adequate day 36 sample. These studies were approved by the St Jude Institutional Review Board.
Treatment protocol
Patients were enrolled in successive St Jude treatment protocols for relapsed ALL. 10, 33, 34 Remission induction treatment included dexamethasone, vincristine and asparaginase, as well as etoposide or topotecan. Intrathecal injection of methotrexate, hydrocortisone and cytarabine were also administered during remission induction as CNS-directed therapy. The patients who achieved morphologic remission (n ¼ 35) received two courses of consolidation therapy followed by continuation chemotherapy. Of these, 10 received hematopoietic stem cell transplantation, three from a related donor and seven from an unrelated donor. It should be noted that MRD results were not communicated to the physicians and were not a factor in treatment decisions.
Flow cytometric assessment of MRD
Bone marrow aspirates were collected in preservative-free heparin. Leukemia-associated immunophenotypes (patterns of cell markers expressed on leukemic cells but not on normal bone marrow cells) were identified by flow cytometry with various combinations of monoclonal antibodies and/or heterologous antisera conjugated to fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein and allophycocyanin. 22, 24, 31, 32, 35, 36 Matched nonreactive fluorochrome-conjugated antibodies were used as controls. The staining procedure has been described. 32 For each case, one or more marker combinations that allowed the identification of one leukemic cell in 10 4 or more normal nucleated bone marrow cells were selected at diagnosis or at first relapse and applied to study MRD at the end of remission induction. 32 In the early part of the study, we used three-color analysis with a single-laser FACScan flow cytometer; after August 1998, all samples were assayed by fourcolor analysis and analyzed with a dual laser-FACScalibur flow cytometer (both cytometers were from Becton Dickinson, San Jose, CA, USA). The flow cytometry protocol used for MRD detection has been described in detail previously. 32 In each test of each sample, we acquired data from more than 10 5 mononuclear cells. Detectable MRD was defined as 0.01% or more leukemic cells among mononuclear cells in the sample.
Statistical analysis
Differences in the distributions of clinical and cellular features by the presence or absence of MRD at day 36 were compared by the Fisher's exact test. The cumulative incidence of second ALL relapse was estimated by the method of Kalbfleisch and Prentice, 37 which accounts for competing risks (second malignancies and deaths during remission) and compared by Gray's test stratified for treatment protocol, and for chemotherapy alone or hematopoietic stem cell transplantation. 38 The cutoff date of follow-up observations was May 2003. Time at risk was calculated from the date of second remission until the date of relapse, occurrence of a competing event or the date of last contact for patients who experienced no event. The significance of the presence or absence of MRD and other factors of potential prognostic value (time of relapse, site of relapse, cell lineage and percentage of circulating blasts at first relapse) were analyzed in the proportional-hazards model suggested by Fine and Gray. 39 The factors found significant in the univariate analyses were then analyzed jointly in a multivariate manner. Hazard ratios and their associated 95% confidence intervals were calculated from the coefficients and standard errors estimated by the model.
Results
Prevalence of MRD after remission reinduction and its relation with clinical and cellular features
We prospectively measured the percentage of residual leukemic cells among bone marrow mononuclear cells collected after remission reinduction (day 36) in the 41 patients with a leukemia-associated immunophenotype. Six of these patients failed to achieve remission with the scheduled course of remission induction therapy and all had leukemic cells detectable by flow cytometry. Of the remaining 35 patients who achieved a second morphologic remission, 19 (54%) had X0.01% leukemic cells identifiable by flow cytometry in the bone marrow. Among these patients, the levels of leukemia were 0.01-o0.1% in three patients (9%), 0.1-o1% in nine (26%) and X1% in seven (20%). In the remaining 16 patients (46%), leukemic cells were below the limit of detection of our technique (0.01%). Collectively, these results contrast with those obtained in patients with newly diagnosed ALL, 75% of whom were MRD negative at the end of remission induction; among those who were MRD positive, the levels of MRD X1% were infrequent (Figure 1a) . 24 However, a direct comparison of MRD levels measured at first and second remission date in the same patients indicated similar rates of residual disease: of the 29 patients in whom both measurements were available, MRD Figure 1 Prevalence of MRD after remission induction therapy in patients with relapsed ALL compared to that of patients with newly diagnosed ALL. All patients included in the analysis were in morphologic remission. Identical MRD methodology was used to study MRD in the two groups. (a) Bars show the proportion of patients with no detectable MRD (MRD negative) and with various levels of MRD (MRD positive) at first and second complete remission (CR). MRD data in patients with newly diagnosed ALL have been reported previously. 24 (b) Prevalence of MRD in a group of 29 patients studied at first and second CR.
Residual (Figure 1b) . The presence or absence of residual leukemia by flow cytometry at day 36 was not significantly related to age, gender, time of relapse or presence of circulating blasts at relapse, although four out of five patients with peripheral blood lymphoblasts X10 Â 10 9 /l had MRD (Table 1 ). All four patients with first extramedullary relapse (central nervous system (CNS) ¼ 3; testicular ¼ 1) were MRD negative at day 36 ( Table 1) . Rates of detection did not differ significantly according to cell lineage, presence of the Philadelphia chromosome, 11q23 abnormalities or TEL/AML1 transcripts, or ploidy. It is worth noting, however, that four of eight patients with B-lineage ALL and hyperdiploidy (51-65 chromosomes) or TEL gene rearrangements were MRD positive after remission induction. Among patients with newly diagnosed ALL, only 10 of 57 with those abnormalities were MRD positive (P ¼ 0.058). 24 
Detection of MRD and risk of second leukemia relapse
We determined the prognostic impact of MRD in the cohort of 35 patients who achieved morphologic remission after the scheduled remission reinduction therapy. The 2-year cumulative incidence of relapse for the 19 patients with detectable (X0.01%) leukemic cells at day 36 was 70.2712.3 vs 27.9712.4% for the 16 patients with negative findings (P ¼ 0.008; Figure 2 ). All 12 second relapses in the MRDpositive group were hematological and nine of these occurred within 6 months after first relapse. By contrast, of the five relapses in the MRD-negative group, three were hematological and occurred 4, 7 and 25 months after first relapse; the other two second relapses in this group were limited to the CNS and occurred in patients who had isolated CNS first relapses. After excluding the four patients who had an isolated extramedullary first relapse (all of whom were MRD negative at day 36) from the analysis, the 2-year cumulative incidence of relapse for the 12 MRD-negative patients was 18.2712.3% (P ¼ 0.013). The leukemia-associated immunophenotypes used to monitor MRD were retained in all 14 patients tested at the time of second hematological relapse (11 of the 12 in the MRD-positive group and all three in the MRD-negative group). Therefore, negative MRD findings at day 36 in these patients could not be attributed to immunophenotypic shifts.
MRD was a significant predictor of outcome in patients who had their first relapse after cessation of therapy: in this group, 2-year cumulative incidence of relapse for the 12 patients with a positive MRD test was 49.1717.8 vs 0% for the 11 MRDnegative patients (P ¼ 0.014). Five of 12 patients with detectable MRD relapsed, all within 1 year of the MRD assay. By contrast, only one of the 11 MRD-negative patients relapsed 25 months after the negative MRD assay. The 2-year relapse rate did not change if the two patients who had an isolated extramedullary relapse off therapy were removed from the MRD-negative group (P ¼ 0.026). As expected, the 12 patients who relapsed on therapy had a dismal outcome: all seven who were MRD positive at day 36 relapsed, as did four of five who were MRD negative. Therefore, relapse on therapy carries a high risk of second relapse irrespective of achievement of MRD negativity after remission reinduction.
Of the 35 patients included in the study, 25 were treated with chemotherapy only and 10 received subsequent hematopoietic Figure 2 Cumulative incidence of relapse in patients with relapsed ALL according to MRD after remission induction therapy. All patients included in the analysis were in morphologic remission at the time of the MRD assay. Residual leukemic lymphoblasts after relapse E Coustan-Smith et al stem cell transplant. Among patients who received chemotherapy alone after first relapse, 2-year cumulative incidence of second relapse was 81.5714.4% for the 12 MRD-positive patients and 25.0713.1% for the 13 MRD-negative patients (P ¼ 0.004). Seven of the 10 patients who received hematopoietic stem cell transplantation were MRD positive at the end of remission reinduction: three relapsed post-transplant, two died of transplant-related complications and two were in remission at the time of this analysis. The remaining three patients were MRD negative: one relapsed post-transplant, one died of complications and one is in remission.
As shown in Table 2 , on-therapy relapse and the presence of MRD at day 36 were independently associated with subsequent leukemia relapse. MRD at the end of remission reinduction after adjusting for the effect of time of relapse was associated with a risk ratio of 3.40 (95% confidence interval: 1.40-8.23; P ¼ 0.007).
Discussion
MRD assays are increasingly used to adjust the intensity of treatment in patients with ALL and have been incorporated in frontline protocols. 40 The results of this prospective study indicate that MRD monitoring by flow cytometry could also be helpful in the clinical management of patients with relapsed ALL. We found that approximately half of patients with relapsed ALL who achieved a morphologic remission have 0.01% or more residual leukemic cells in bone marrow and that this finding was associated with a significantly higher risk of a second leukemia relapse. In particular, MRD was a strong predictor of outcome among patients who had a first relapse off therapy. By contrast, patients who had a first relapse on therapy did poorly irrespective of achieving MRD-negative status at the end of remission induction.
The reported experience on the clinical significance of MRD after second remission induction in patients with relapsed ALL is scanty. Steenbergen et al 29 used polymerase chain reaction (PCR) amplification of antigen-receptor genes and archived samples to compare MRD after remission induction in patients with newly diagnosed and relapsed B-lineage ALL. MRD was detectable in only two of the 18 newly diagnosed patients but in 10 of the 16 with relapsed disease. We also found that the prevalence of MRD at the time of second remission was markedly higher than that determined at first remission (54 vs 25%), and that the levels of residual leukemia among MRDpositive patients in second remission were higher. However, because MRD in first remission was more prevalent in the group of patients who subsequently relapsed, MRD measurements at first and second remission were similar when directly compared in the same group of patients. In a retrospective study of bone marrow samples collected from 26 patients with relapsed ALL treated in the ALL-REZ BFM studies, Eckert et al 30 found that levels of MRD X0.1% at the end of remission reinduction, as determined by PCR amplification of clonal immunoglobulin or T-cell receptor genes, was associated with a poorer event-free survival. Our results generally agree with this finding and demonstrate that the presence of MRD after remission reinduction is directly and independently associated with a second recurrence of leukemia. In our study, the 0.01% cutoff appeared to be more informative than the 0.1% level use by Eckert et al; all three patients with MRD X0.01% but o0.1% subsequently relapsed.
Bone marrow relapse is the most frequent indication for allogeneic hematopoietic stem cell transplantation in children. 41 As only 10 patients received transplantation, our study does not clarify the significance of MRD at the end of remission reinduction in this context. However, other studies have shown that sequential MRD monitoring before and after transplant may be useful to help select clinical strategies. 29, [42] [43] [44] [45] [46] Owing to the toxicities associated with transplantation, it is important to identify patients who can be cured with chemotherapy alone. We suggest that MRD assays postremission induction could be particularly useful in patients with 'standard risk' relapsed ALL (ie those who have a hematologic relapse off therapy). In our current treatment plan for relapsed ALL, a high level of MRD (X1%) after a 6-week remission induction is an indication for allogeneic hematopoietic stem cell transplant, even for patients with off-therapy relapse. MRD is then sequentially monitored and transplant is performed as soon as MRD is reduced by intensive consolidation therapy and a suitable donor is available. Patients with off-therapy relapse and lower levels of detectable MRD (X0.01-o1%) after remission will be closely monitored and offered a transplant if MRD persists. Residual leukemic lymphoblasts after relapse E Coustan-Smith et al
